HK1213777A1 - 在胰岛移植中作为佐剂的cxcr1/2抑制剂 - Google Patents

在胰岛移植中作为佐剂的cxcr1/2抑制剂 Download PDF

Info

Publication number
HK1213777A1
HK1213777A1 HK16101720.7A HK16101720A HK1213777A1 HK 1213777 A1 HK1213777 A1 HK 1213777A1 HK 16101720 A HK16101720 A HK 16101720A HK 1213777 A1 HK1213777 A1 HK 1213777A1
Authority
HK
Hong Kong
Prior art keywords
transplantation
mice
islet
raparicin
cxcr1
Prior art date
Application number
HK16101720.7A
Other languages
English (en)
Chinese (zh)
Inventor
洛倫佐．皮耶蒙蒂
洛伦佐．皮耶蒙蒂
路易莎．達豐希奧
路易莎．达丰希奥
馬爾塞洛．阿萊格雷蒂
马尔塞洛．阿莱格雷蒂
Original Assignee
多姆皮制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 多姆皮制药公司 filed Critical 多姆皮制药公司
Publication of HK1213777A1 publication Critical patent/HK1213777A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16101720.7A 2009-10-06 2016-02-18 在胰岛移植中作为佐剂的cxcr1/2抑制剂 HK1213777A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172364.3 2009-10-06
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Publications (1)

Publication Number Publication Date
HK1213777A1 true HK1213777A1 (zh) 2016-07-15

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101720.7A HK1213777A1 (zh) 2009-10-06 2016-02-18 在胰岛移植中作为佐剂的cxcr1/2抑制剂

Country Status (24)

Country Link
US (1) US20120202884A1 (https=)
EP (2) EP2308484A1 (https=)
JP (2) JP5834010B2 (https=)
KR (2) KR101759362B1 (https=)
CN (2) CN104906572A (https=)
AU (1) AU2010305385B2 (https=)
BR (1) BR112012007991B8 (https=)
CA (1) CA2775902C (https=)
CY (1) CY1115018T1 (https=)
DK (1) DK2485723T3 (https=)
EA (1) EA021298B1 (https=)
ES (1) ES2451349T3 (https=)
HK (1) HK1213777A1 (https=)
HR (1) HRP20140202T1 (https=)
IL (1) IL219037A (https=)
ME (1) ME01719B (https=)
MX (1) MX2012004082A (https=)
NZ (1) NZ599172A (https=)
PL (1) PL2485723T3 (https=)
PT (1) PT2485723E (https=)
RS (1) RS53249B (https=)
SI (1) SI2485723T1 (https=)
SM (1) SMT201400033B (https=)
WO (1) WO2011042466A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
US11291641B2 (en) * 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
ATE444286T1 (de) 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
PT1579859E (pt) 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
EP1790637B1 (en) * 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
WO2008039876A1 (en) * 2006-09-26 2008-04-03 Case Western Reserve University Cytokine signaling
CN102088993A (zh) 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
CN104906572A (zh) 2015-09-16
JP2015145404A (ja) 2015-08-13
EA021298B1 (ru) 2015-05-29
IL219037A0 (en) 2012-06-28
KR101759362B1 (ko) 2017-07-18
PL2485723T3 (pl) 2014-07-31
BR112012007991A2 (pt) 2017-07-25
JP6097328B2 (ja) 2017-03-15
US20120202884A1 (en) 2012-08-09
CA2775902A1 (en) 2011-04-14
KR101817912B1 (ko) 2018-02-21
BR112012007991B1 (pt) 2020-12-15
CN102665703B (zh) 2016-04-20
ME01719B (me) 2014-09-20
SMT201400033B (it) 2014-07-07
EP2308484A1 (en) 2011-04-13
AU2010305385B2 (en) 2016-04-21
CN102665703A (zh) 2012-09-12
SI2485723T1 (sl) 2014-06-30
HK1175993A1 (zh) 2013-07-19
EP2485723B1 (en) 2013-12-11
JP2013506704A (ja) 2013-02-28
WO2011042466A1 (en) 2011-04-14
HRP20140202T1 (en) 2014-05-23
BR112012007991B8 (pt) 2021-05-25
JP5834010B2 (ja) 2015-12-16
CY1115018T1 (el) 2017-01-25
IL219037A (en) 2015-01-29
KR20170068625A (ko) 2017-06-19
PT2485723E (pt) 2014-03-13
CA2775902C (en) 2016-11-29
ES2451349T3 (es) 2014-03-26
NZ599172A (en) 2014-03-28
MX2012004082A (es) 2012-07-25
KR20120083440A (ko) 2012-07-25
RS53249B (sr) 2014-08-29
AU2010305385A1 (en) 2012-04-26
EP2485723A1 (en) 2012-08-15
EA201270513A1 (ru) 2012-11-30
DK2485723T3 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
KR101650264B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
HK1213777A1 (zh) 在胰岛移植中作为佐剂的cxcr1/2抑制剂
AU2018201965B2 (en) CTLA4 fusion proteins for the treatment of diabetes
MXPA04010170A (es) Medicamento para prevenir y/o tratar el rechazo cronico.
EP1429845B1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
EP3056218A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
KR101737656B1 (ko) 당뇨병의 예방을 위한 설폰아마이드
Klintmalm A review of FK506: a new immunosuppressant agent for the prevention and rescue of graft rejection
US11969397B2 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
HK1175993B (en) Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
US20090155260A1 (en) Use of thymosin alpha 1 for the treatment of immunological diseases
Gabardi et al. Immunosuppressive Pharmacotherapy
JPH08157364A (ja) 免疫拒絶反応抑制剤
HK1174557B (en) Sulfonamides for the prevention of diabetes